Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Fabrizio

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The American Journal of Managed Care|July 9, 2020
Addressing the gap in precision medicineDavid A Fabrizio
JAMA Oncology|September 4, 2020
Demystifying the Role of Tumor Mutational Burden for Immunotherapy SelectionDavid A Fabrizio, Priti Hegde, Brian Alexander
The Journal of Biological Chemistry|October 12, 2004
Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free systemElisabetta del Re, Yisrael Sidis, David A Fabrizio, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 27, 2004
DRAGON: a member of the repulsive guidance molecule-related family of neuronal- and muscle-expressed membrane proteins is regulated by DRG11 and has neuronal adhesive propertiesTarek A Samad, Ashok Srinivasan, Laurie A Karchewski, et al.
The Journal of Biological Chemistry|January 27, 2005
DRAGON, a bone morphogenetic protein co-receptorTarek A Samad, Anuradha Rebbapragada, Esther Bell, et al.
Journal of Gastrointestinal Oncology|August 29, 2018
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibitionDavid A Fabrizio, Thomas J George, Richard F Dunne, et al.
Nature Medicine|April 15, 2022
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trialEdward S Kim, Vamsidhar Velcheti, Tarek Mekhail, et al.
The Journal of Molecular Diagnostics : JMD|August 25, 2019
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient SamplesSally E Trabucco, Kyle Gowen, Sophia L Maund, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The American Journal of Managed Care|July 9, 2020
Addressing the gap in precision medicineDavid A Fabrizio
JAMA Oncology|September 4, 2020
Demystifying the Role of Tumor Mutational Burden for Immunotherapy SelectionDavid A Fabrizio, Priti Hegde, Brian Alexander
The Journal of Biological Chemistry|October 12, 2004
Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free systemElisabetta del Re, Yisrael Sidis, David A Fabrizio, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 27, 2004
DRAGON: a member of the repulsive guidance molecule-related family of neuronal- and muscle-expressed membrane proteins is regulated by DRG11 and has neuronal adhesive propertiesTarek A Samad, Ashok Srinivasan, Laurie A Karchewski, et al.
The Journal of Biological Chemistry|January 27, 2005
DRAGON, a bone morphogenetic protein co-receptorTarek A Samad, Anuradha Rebbapragada, Esther Bell, et al.
Journal of Gastrointestinal Oncology|August 29, 2018
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibitionDavid A Fabrizio, Thomas J George, Richard F Dunne, et al.
Nature Medicine|April 15, 2022
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trialEdward S Kim, Vamsidhar Velcheti, Tarek Mekhail, et al.
The Journal of Molecular Diagnostics : JMD|August 25, 2019
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient SamplesSally E Trabucco, Kyle Gowen, Sophia L Maund, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.
Pageof 1